Craig Bottomley
Plus aucun poste en cours
Profil
Craig Bottomley is the founder of Halcygen Pharmaceuticals Ltd., which was founded in 2005.
He held the title of Chief Operating Officer & Executive Director from 2005 to 2010.
Mr. Bottomley's former jobs include Managing Director at GUD Holdings Ltd., Director at Mirrabooka Investments Ltd., Managing Director at Pacific Dunlop Cables Group, and Non-Executive Director at BWX Ltd.
from 2013 to 2017.
He also held the position of Non-Executive Director at Star Combo Pharma Ltd.
in 2019.
Anciens postes connus de Craig Bottomley
| Sociétés | Poste | Fin |
|---|---|---|
| STAR COMBO PHARMA LIMITED | Directeur/Membre du Conseil | 16/08/2019 |
| BWX | Directeur/Membre du Conseil | 02/03/2017 |
Halcygen Pharmaceuticals Ltd.
 Halcygen Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Halcygen Pharmaceuticals Ltd. engages in development and licensing of new improved proprietary generic formulations known as Super Generics or High Functionality Generics. Halcygen Pharmaceuticals products includes: Suba Itraconazole is a super-bioavailable formulation of itraconazole, a synthetic broad-spectrum anti-fungal agent and Minocycline is used to treat bacterial infections including respiratory tract infections, infections of skin, genital and urinary systems. The company is headquartered in Melbourne, Australia. | Fondateur | 22/11/2010 |
| MAYNE PHARMA GROUP LIMITED | Directeur des opérations | 29/07/2010 |
| GUD HOLDINGS LIMITED | Directeur Général | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| MAYNE PHARMA GROUP LIMITED | Health Technology |
| BWX | Consumer Non-Durables |
| GUD HOLDINGS LIMITED | Consumer Durables |
| STAR COMBO PHARMA LIMITED | Health Technology |
| Entreprise privées | 3 |
|---|---|
Halcygen Pharmaceuticals Ltd.
Halcygen Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Halcygen Pharmaceuticals Ltd. engages in development and licensing of new improved proprietary generic formulations known as Super Generics or High Functionality Generics. Halcygen Pharmaceuticals products includes: Suba Itraconazole is a super-bioavailable formulation of itraconazole, a synthetic broad-spectrum anti-fungal agent and Minocycline is used to treat bacterial infections including respiratory tract infections, infections of skin, genital and urinary systems. The company is headquartered in Melbourne, Australia. | Health Technology |
Mirrabooka Investments Ltd.
 Mirrabooka Investments Ltd. Investment Trusts/Mutual FundsMiscellaneous Mirrabooka Investments Ltd. is closed-end investment fund/Investment trust. It invests in small and medium sized companies located in Australia and New Zealand. The company was founded in December 1998 and is headquartered in Melbourne, Australia. | Miscellaneous |
| Pacific Dunlop Cables Group |